15.58 USD
-0.05
0.32%
At close Apr 23, 4:00 PM EDT
After hours
15.91
+0.33
2.12%
1 day
-0.32%
5 days
2.03%
1 month
-18.00%
3 months
-9.73%
6 months
-12.67%
Year to date
-8.14%
1 year
-10.31%
5 years
35.60%
10 years
129.46%
 

About: InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

Employees: 599

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

0% less call options, than puts

Call options by funds: $28.8M | Put options by funds: $28.9M

2% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 45

2.55% less ownership

Funds ownership: 54.49% [Q3] → 51.93% (-2.55%) [Q4]

3% less funds holding

Funds holding: 252 [Q3] → 245 (-7) [Q4]

6% less capital invested

Capital invested by funds: $781M [Q3] → $734M (-$47.2M) [Q4]

34% less repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 98

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$15
4%
downside
Avg. target
$22
41%
upside
High target
$29
86%
upside

2 analyst ratings

positive
50%
neutral
50%
negative
0%
Jefferies
Matthew Taylor
33% 1-year accuracy
1 / 3 met price target
4%downside
$15
Hold
Maintained
14 Apr 2025
Barclays
Matt Miksic
40% 1-year accuracy
16 / 40 met price target
86%upside
$29
Overweight
Maintained
5 Feb 2025

Financial journalist opinion

Based on 6 articles about INMD published over the past 30 days

Negative
Zacks Investment Research
2 days ago
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
Positive
Zacks Investment Research
1 week ago
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
Positive
Seeking Alpha
2 weeks ago
InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)
I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels.
InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)
Positive
Zacks Investment Research
4 weeks ago
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
Neutral
PRNewsWire
4 weeks ago
InMode to Present at the 24th Annual Needham Virtual Healthcare Conference
YOKNEAM, Israel , March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025.
InMode to Present at the 24th Annual Needham Virtual Healthcare Conference
Positive
Zacks Investment Research
4 weeks ago
Is InMode (INMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is InMode (INMD) Stock Undervalued Right Now?
Neutral
PRNewsWire
1 month ago
InMode Responds to Doma Perpetual's Letters
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel , March 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025.
InMode Responds to Doma Perpetual's Letters
Neutral
PRNewsWire
1 month ago
InMode to Present at Upcoming Investor Conferences
YOKNEAM, Israel , March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 27th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer  Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 12 at 9:00 am EDT A live webcast of the presentation can be accessed here.
InMode to Present at Upcoming Investor Conferences
Positive
Seeking Alpha
2 months ago
InMode: Plastic Surgery Boom, Cash Flow, And Cheap
InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability.
InMode: Plastic Surgery Boom, Cash Flow, And Cheap
Neutral
Seeking Alpha
2 months ago
InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript
InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call.
InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™